Stephane Bancel, Chief Executive, Moderna: We have a number of new vaccines in development, for example against influenza or against the RS virus, which causes a respiratory disease. We can combine these three mRNA vaccines into one dose and propose to governments to secure supplies for a certain amount for several years and then invest in a production facility in that country.

Moderna is not standing around twiddling its thumbs as Omicron threatens to ruin the drug bonanza - they've come up with a strategy to institutionalize mRNA vacs - get the various client countries opening local factories which will create a self-perpetuating incentive to keep the market pumping. Think of all the jobs it will create!